Sehrish Ashraf | Molecular Biology | Innovative Research Award

Published on by Molecular Biologist

 

Innovative Research Award

Sehrish Ashraf

Emerson University Multan, Pakistan

Sehrish Ashraf
Affiliation Emerson University Multan
Country Pakistan
Google Scholar ID rcsbaYAAAAJ
Documents 10
Citations 120
h-index 6
Subject area Molecular Biology
Event International Molecular Biologist Awards
ORCID 0009-0006-9527-6617
Scopus 57202251393

Sehrish Ashraf is a researcher affiliated with Emerson University Multan, Pakistan, whose stated subject area is molecular biology. This academic recognition profile presents the available researcher identifiers, reported bibliometric indicators, and the context of the Innovative Research Award associated with the International Molecular Biologist Awards. Bibliometric values are included as supplied profile data and should be interpreted in relation to their source and retrieval date. [1] [2].

Abstract

Sehrish Ashraf, affiliated with Emerson University Multan in Pakistan, and identifies molecular biology as the stated subject area. [1] [2] The profile also lists an ORCID identifier and a Scopus author record, which can help readers distinguish the researcher’s records and locate associated scholarly outputs. [3] The Innovative Research Award is presented here in the context of the International Molecular Biologist Awards. The available information does not independently establish the award’s assessment outcome, the specific works evaluated, or the methodology used for selection. [4]

Keywords

Sehrish Ashraf; molecular biology; academic research; scholarly publications; research metrics; citation analysis; ORCID; Scopus; Google Scholar; Innovative Research Award; Pakistan; International Molecular Biologist Awards.

Introduction

Molecular biology examines biological processes at the molecular level, including the structure and function of nucleic acids, proteins, and their interactions within cells. Research in this field supports investigations into cellular mechanisms, gene regulation, molecular interactions, and biological systems. Individual researcher profiles can help readers locate scholarly records and understand the broad academic context of a researcher’s work.

Sehrish Ashraf is identified in the supplied information as being affiliated with Emerson University Multan, Pakistan. Molecular biology is listed as the relevant subject area. The identifiers supplied for the researcher include an ORCID profile, a Scopus author profile, and a Google Scholar profile. These services provide different mechanisms for identifying researchers and retrieving publication-related information. [1] [2] [3]

Research Profile

The supplied academic details associate Sehrish Ashraf with Emerson University Multan and the discipline of molecular biology. The following summary reproduces the identifiers and bibliometric figures provided for this profile. The figures have not been independently audited for this article, and a retrieval date was not supplied.

ORCID provides persistent researcher identifiers intended to distinguish individuals and connect their scholarly activities. Scopus author records organize publications and related metrics indexed by Scopus, while Google Scholar profiles present scholarly records and citation information drawn from Google Scholar’s indexing system. Differences in coverage and record matching mean that figures from these services should not automatically be treated as interchangeable. [1] [2] [3]

Research Contributions

The supplied information identifies molecular biology as the researcher’s subject area but does not include a verified publication list, article titles, abstracts, experimental methods, or descriptions of individual findings. Consequently, specific discoveries, techniques, or scientific advances cannot be attributed to Sehrish Ashraf from the available data alone. A detailed assessment of research contributions would require examination of the researcher’s publications and their documented findings.

A publication-based review may examine the following dimensions where reliable evidence is available:

  • The scientific questions addressed and their relevance to molecular biology.
  • The research methods, experimental design, analytical approaches, and reproducibility of reported findings.

Publications

The supplied profile reports 10 documents. However, individual publication metadata, including titles, journal names, publication years, author order, and digital object identifiers (DOIs), were not provided as part of the input data. The figure should therefore be treated as a reported profile statistic rather than a verified bibliography. Readers can consult the researcher’s linked Scopus and Google Scholar records for publication details and any available citation information. [1] [2]

For a complete publication record, each entry should be checked against the publisher’s version of record. Where available, a DOI should be included as a persistent link to the corresponding publication.

Research Impact

The supplied bibliometric information reports 120 citations and an h-index of 6. The h-index is a bibliometric indicator that combines publication output and citation counts: a researcher has an h-index of at least h when h publications have each received at least h citations. Citation counts and h-index values are dependent on database coverage, author-name disambiguation, document types, and the date on which records are retrieved. [2] [5]

The reported figures provide one quantitative view of the available research profile. A fuller assessment would consider the content and reliability of individual publications, the contribution of the researcher to collaborative work, the context in which citations occur, and evidence of influence on further research or practical applications.

Award Suitability

The title associated with this article is the Innovative Research Award, presented in the context of the International Molecular Biologist Awards. The supplied information establishes the intended recognition category and identifies the researcher’s institution, subject area, and reported bibliometric indicators. It does not provide an official award decision, selection notice, judging rubric, or evidence documenting the specific research achievements assessed by the organizers.

A transparent assessment of suitability for an innovative research award would ordinarily consider evidence such as:

  1. Originality of the research question, approach, or resulting knowledge.
  2. Methodological rigor and the reproducibility of reported findings.
  3. Documented contribution to the relevant field and distinction from prior work.

Conclusion

Sehrish Ashraf is identified in the supplied profile as a researcher affiliated with Emerson University Multan, Pakistan, with molecular biology listed as the subject area.  A comprehensive account of scientific contributions and research impact would require verification of individual publications, their findings, and the researcher’s documented role in the work. The Innovative Research Award designation is included as the stated recognition context, while confirmation of a formal award outcome should be based on verifiable organizer documentation.

References

  1. Elsevier. (n.d.). Scopus author details: Sehrish Ashraf, Author ID 57202251393. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57202251393
  2. Google. (n.d.). Google Scholar profile: Sehrish Ashraf, user ID 0rcsbaYAAAAJ.
    https://scholar.google.com.tr/citations?user=0rcsbaYAAAAJ&hl=lv
  3. ORCID. (n.d.). ORCID record: Sehrish Ashraf, ORCID iD 0009-0006-9527-6617.
    https://orcid.org/0009-0006-9527-6617
  4. International Molecular Biologist Awards. (n.d.). Official award website.
    https://molecularbiologist.org/
  5. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.
    https://doi.org/10.1073/pnas.0507655102

Promy Virk | Molecular Biology | Innovative Molecular Biologist Award

Published on by Molecular Biologist

Innovative Molecular Biologist Award

Promy Virk
King Saud University, Saudi Arabia

Promy Virk
Affiliation King Saud University
Country Saudi Arabia
Google Scholar ID clmjNO4AAAAJ
Citations 1,788
h-index 30
i10 index 22
Subject Area Molecular Biology
Event International Molecular Biologist Awards
ORCID 0000-0002-4030-7651
Scopus 55131550000

Promy Virk is a molecular biology researcher affiliated with King Saud University in Saudi Arabia. The researcher’s academic profile is associated with molecular biology and can be identified through persistent researcher identifiers and scholarly indexing services, including ORCID, Scopus, and Google Scholar. The available scholarly profile information records 1,788 citations, an h-index of 30, and an i10 index of 22 at the time of compilation. [1] [2] [3]

Abstract

Promy Virk, a researcher affiliated with King Saud University, Saudi Arabia, whose stated subject area is molecular biology. The profile consolidates researcher-identification information, bibliometric indicators, institutional affiliation, and award context into a structured academic format. According to the supplied scholarly profile information, the researcher has a Google Scholar h-index of 30, an i10 index of 22, and 1,788 citations. [1] [2] The recognition discussed on this page is connected with the International Molecular Biologist Awards.

Keywords

  • Promy Virk
  • Molecular Biology
  • King Saud University
  • Saudi Arabia

Introduction

Molecular biology examines biological processes at the molecular level, including the organization, expression, regulation, and interaction of biological macromolecules. Contemporary molecular biology relies on integrated experimental and computational approaches to investigate biological systems and to translate molecular observations into reproducible scientific knowledge. Standard molecular biology methodologies have contributed substantially to the characterization and quantification of biological processes across diverse research settings. [5]

Within this broad discipline, researcher identification and scholarly attribution are increasingly supported by persistent identifiers and bibliographic databases. ORCID provides a persistent digital identifier intended to distinguish researchers and connect them with their scholarly contributions, while Scopus and Google Scholar provide mechanisms for discovering and evaluating indexed scholarly output. [2] [1] [3]

Research Profile

Promy Virk is identified in the supplied academic information as a molecular biology researcher affiliated with King Saud University in Saudi Arabia. The research profile includes a Google Scholar identifier, ORCID identifier, and Scopus author identifier, enabling the researcher to be distinguished across several scholarly information systems. [1] [2] [3]

The bibliometric indicators supplied for this profile include 1,788 citations, an h-index of 30, and an i10 index of 22. Such indicators are commonly used as quantitative descriptors of scholarly visibility and citation activity, although they should be interpreted in relation to disciplinary practices, publication history, database coverage, authorship patterns, and the date on which the metrics are observed. [3]

Research Contributions

The available profile information places Promy Virk within the field of molecular biology. A researcher operating in this field may contribute through experimental investigation, molecular characterization, biological mechanism studies, methodological development, collaborative research, and dissemination of findings through peer-reviewed scholarly publications. The specific contribution of an individual researcher is best assessed through the primary literature, author-level publication records, and independently verifiable institutional information.

The presence of a persistent ORCID identifier provides a mechanism for connecting scholarly works with the researcher and reducing ambiguity arising from variations in author names. [2] The associated Scopus author profile provides an additional bibliographic record through which publication and citation information may be examined. [1]

  • Research activity within the broad discipline of molecular biology.
  • Scholarly visibility represented through indexed citation metrics.
  • Persistent researcher identification through ORCID, Scopus, and Google Scholar.

Publications

Publication records are an important component of evaluating research activity because they provide the primary scholarly record of scientific findings. For Promy Virk, publication information can be explored through the researcher’s Scopus author record and Google Scholar profile. [1] [3] These databases may differ in their coverage, author disambiguation procedures, citation calculations, and update schedules; therefore, bibliometric values should be considered database-specific rather than universal measures of research performance.

Persistent identifiers and indexed author profiles are particularly useful when assessing publication records over time because they can assist in distinguishing authors with similar or identical names. ORCID provides an identifier designed for this purpose, while bibliographic services provide complementary publication and citation information. [2]

Research Impact

The supplied Google Scholar metrics indicate 1,788 citations, an h-index of 30, and an i10 index of 22. [3] These values provide quantitative information about the citation history represented in the corresponding Google Scholar profile. Citation indicators can assist in describing scholarly reach, but they do not independently establish the quality, originality, societal value, or practical significance of individual research contributions.

Research impact in molecular biology can be considered through multiple dimensions, including influence on subsequent scientific studies, methodological adoption, collaboration, education, translational relevance, and contribution to understanding biological mechanisms. A balanced assessment therefore combines bibliometric indicators with examination of publications, research context, peer recognition, and independently verifiable evidence.

Award Suitability

The supplied academic profile identifies Promy Virk with a molecular biology research background, an affiliation with King Saud University, and measurable scholarly activity represented by citation and author-index indicators. These characteristics provide a factual basis for considering the researcher within an academic recognition framework focused on molecular biology. [1] [3]

The Innovative Molecular Biologist Award is presented here in the context of the International Molecular Biologist Awards. Award suitability should ultimately be determined according to the event’s published eligibility criteria, nomination procedures, review process, and independently verifiable evidence of research contributions. The official award website provides the appropriate source for current event information and requirements. [4]

Conclusion

Promy Virk is an academic researcher affiliated with King Saud University in Saudi Arabia and identified within the subject area of molecular biology. The supplied scholarly indicators record 1,788 citations, an h-index of 30, and an i10 index of 22, while ORCID, Scopus, and Google Scholar identifiers provide complementary mechanisms for researcher identification and scholarly discovery. [1] [2] [3]

The profile provides a structured academic basis for recognition under the Innovative Molecular Biologist Award category associated with the International Molecular Biologist Awards. Assessment of research excellence should remain grounded in the primary scholarly record, institutional information, transparent award criteria, and appropriately contextualized bibliometric evidence.

References

  1. Elsevier. (n.d.). Scopus author details: Promy Virk, Author ID 55131550000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=55131550000
  2. ORCID. (n.d.). ORCID record: Promy Virk. ORCID.
    https://orcid.org/0000-0002-4030-7651
  3. Google Scholar. (n.d.). Google Scholar profile: Promy Virk. Google Scholar.
    https://scholar.google.com/citations?user=clmjNO4AAAAJ&hl=en&authuser=1
  4. International Molecular Biologist Awards. (n.d.). International Molecular Biologist Awards — Official Website.
    https://molecularbiologist.org/
  5. Bustin, S. A., et al. (2009). The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clinical Chemistry.
    https://doi.org/10.1373/clinchem.2008.112797

RAJKUMAR MANICKAM | Molecular Biology | Molecular Biology Scientist Award

Published on by Molecular Biologist

Assist. Prof. Dr. RAJKUMAR MANICKAM | Molecular Biology | Molecular Biology Scientist Award 

Assistant Professor | Karpagam Academy of Higher Education | India

Assist. Prof. Dr. Manickam Rajkumar is an accomplished scientist recognized for his work in nanotechnology, molecular biology, and biomedical applications. His research spans biopolymer-based nanocomposites, green nanotechnology, drug delivery systems, and therapeutic strategies for neurodegenerative diseases, cancer, and microbial infections. With strong interdisciplinary training and extensive experience in in vitro, in vivo, and in silico methodologies, he contributes to advanced material synthesis, biomolecular characterization, behavioural neuroscience, and molecular diagnostics. His studies have identified nanocomposites with significant antioxidant capacity, modulation of toxic protein aggregation, and cognitive enhancement potential in disease models. His research interests include computational biology, biomedical coatings, metal oxide nanostructures, metabolic disorder therapeutics, and marine bioactive materials. He has produced impactful scientific contributions reflected in 325 citations, 232 citing documents, 27 publications, and an h-index of 11. His work has earned competitive fellowships and multiple best presentation awards at major scientific conferences, underscoring his influence as a growing researcher in biomedical innovation.

Profiles: Scopus | ORCID | Google Scholar
Featured Publications

Biosynthesis of cerium oxide nanoparticles. Biomedical Materials & Devices.

Review on green synthesis of nanoparticles. Biomedical Materials & Devices.

Biosynthesis of chitosan–TiO₂ nanoparticles. Inorganic Chemistry Communications.

CuO nanoparticles for colon cancer therapy. Journal of Cluster Science.

NanoMarine therapeutics for colon cancer. Frontiers in Genetics.

Eco-friendly synthesis of ZnO nanoparticles. Inorganic Chemistry Communications.

Weiwei Fu | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Weiwei Fu | Molecular Biology | Best Researcher Award 

Research assistant professor, at Peking University Third Hospital, China.

Dr. Fu Weiwei is an accomplished medical scientist specializing in gastroenterology and immunology. She currently serves as an Assistant Research Professor and Laboratory Director at the Gastroenterology Department, Peking University Third Hospital, where she leads research at the Beijing Key Laboratory. Dr. Fu earned her Ph.D. in Immunology from Peking University Health Science Center and has a strong foundation in traditional medicine, holding a Bachelor of Medicine from Shandong University. With more than a decade of experience in translational medical research, her work bridges cutting-edge immunological discoveries and practical clinical applications. Her focus lies in immune microenvironment dynamics, gastrointestinal tumor evolution, and the integration of traditional Chinese medicine for digestive disease therapies. She has delivered several high-profile international presentations and has published widely in leading scientific journals. Her contributions have significantly advanced the field of digestive immunology.

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Fu’s academic journey began with a 5-year Bachelor of Medicine program at Shandong University of Traditional Chinese Medicine (2002–2007), where she laid a solid foundation in both conventional and traditional healthcare practices. Her early exposure to integrative medicine inspired a unique perspective on digestive health and immune response. Motivated by scientific rigor, she enrolled in the Combined Master’s and Ph.D. Program in Immunology (2008–2013) at Peking University Health Science Center, mentored by Prof. Wenling Han. This elite program sharpened her skills in molecular biology, immunopathology, and clinical translational research. Throughout her doctoral years, she focused on the host immune responses in cancer, particularly those related to gastric inflammation and tumorigenesis. This diverse academic training enables her to merge modern biomedical technologies with traditional insights, giving her an edge in the multidisciplinary field of digestive immunology.

🧪 Experience

Dr. Fu brings a wealth of research and clinical experience to her current position at the Gastroenterology Department, Peking University Third Hospital (2019–present), where she directs the Beijing Key Laboratory. As an Assistant Research Professor, she leads a team focusing on translational immunology in gastrointestinal diseases. Before this, she completed a prestigious postdoctoral fellowship (2013–2019) at the Tsinghua University Institute of Immunology under Prof. Chen Dong, an Academician of the Chinese Academy of Sciences. During this time, she worked on T-cell signaling, immune checkpoints, and the role of lymphoid cells in cancer. Her lab currently integrates clinical cohort data with multi-omics techniques to explore disease mechanisms. She is also instrumental in mentoring junior researchers and clinicians. Her work bridges laboratory immunology with bedside applications, ensuring scientific advancements are translated into improved diagnosis and therapy for patients.

🔬 Research Interests

Dr. Fu’s research centers on the immune microenvironment in gastrointestinal tumors and digestive tract diseases, such as gastric cancer and inflammatory bowel disease. She applies multi-omics technologies—including single-cell RNA sequencing, proteomics, and microbiome analysis—to decipher host-pathogen interactions and immune cell dynamics during disease evolution. A key aspect of her research is understanding how Helicobacter pylori infection initiates gastric lesions, tumor progression, and immune escape. She also investigates traditional Chinese medicine-based therapies, exploring their role in cancer prevention and immune modulation. Another focal point is early screening and biomarker discovery for precancerous lesions through clinical cohort studies. By integrating high-throughput data with clinical insights, her work aims to improve patient stratification and individualized treatments. Her interdisciplinary approach bridges immunology, oncology, and traditional medicine, placing her at the forefront of gastrointestinal research in China and beyond.

🏆 Awards

Dr. Fu’s scientific excellence has been consistently recognized. She won the Outstanding Paper Award at the 2023 Chinese Medical Association’s National Conference on Digestive Diseases (CGC 2023) for her oral presentation on immune profiling during colorectal cancer progression. Her continuous contributions to clinical immunology, translational oncology, and molecular diagnostics have earned her accolades from both national and international platforms. Her selection as an oral presenter at leading conferences—such as DDW 2024 in Washington, D.C., and UEGW 2023 in Copenhagen—speaks to her international recognition. She has also received patent grants for innovations in inflammation and cancer therapy, reflecting her drive for practical applications. As a dedicated researcher, educator, and innovator, Dr. Fu stands out as a top candidate for award nominations in the fields of biomedical research and clinical translational science.

📚 Top Noted Publications

Dr. Fu has authored and co-authored numerous impactful papers in top-tier journals (JCR Q1–Q3), often as first or corresponding author. Below are select publications with hyperlink.

2025

  1. Luteolin Improves Precancerous Gastric Mucosa by Binding STAT3
    International Journal of Biological Sciences (Q1, IF 8.1)
    📌 Co-Corresponding Author
    🧪 Original Research

  2. CMTM3 Regulates Colitis-Associated Cancer Progression
    Cellular and Molecular Gastroenterology and Hepatology (CMGH) (Q1, IF 7.1)
    📌 Co-Corresponding Author
    🧬 Original Research

  3. Cmtm4 Deficiency Exacerbates H. pylori-Induced Gastric Carcinogenesis
    Pathology International (Q2, IF 2.5)
    📌 Co-Corresponding Author
    🦠 Original Research

  4. The Host Immune Response Landscape in Gastric Cancer Development
    Clinical and Experimental Immunology (Q2, IF 3.4)
    📌 First Author
    🧫 Original Research

2024

  1. Neutrophil Heterogeneity in Hepatocellular Carcinoma and Tumor Immunity
    Cancer Medicine (Q2, IF 2.9)
    📌 Co-First Author
    🔬 Original Research

  2. Oxidative Balance in Diet and Sleep Patterns: A Metabolic Interaction
    Frontiers in Nutrition (Q2, IF 4.0)
    📌 Co-First Author
    🍽 Original Research

  3. CMTM4 Facilitates Gastric Cancer Metastasis via EMT Modulation
    Journal of Gastrointestinal Oncology (Q3, IF 2.0)
    📌 Co-First Author
    🧠 Original Research

  4. Cmtm4 Shapes Colitis Outcomes via Microbial Dysbiosis and Mucosal Immunity
    Journal of Genetics and Genomics (Q1, IF 6.6)
    📌 Co-Corresponding Author
    🧪 Original Research

  5. Serum Proteomics-Based Biomarkers of Precancerous Gastric Lesions
    Frontiers in Molecular Biosciences (Q2, IF 3.9)
    📌 Co-Corresponding Author
    🔍 Original Research

  6. Treg Subsets Orchestrate Tumor Microenvironment in Colorectal Cancer
    Frontiers in Immunology (Q1, IF 5.7)
    📌 Co-First & Corresponding Author
    🧫 Original Research

2023

  1. Helicobacter pylori and Inflammasome Activation in Gastric Pathogenesis (Review)
    Helicobacter (Q2, IF 4.3)
    📌 Co-Corresponding Author
    🧯 Review Article

2022

  • Lymphocyte Profile Alterations in Precancerous Gastric Lesions
    Journal of Leukocyte Biology (Q2, IF 5.5)
    📌 First Author
    🧬 Original Research

  • B7 Family Molecules and Immune Evasion in H. pylori Infection (Review)
    Helicobacter (Q2, IF 4.4)
    📌 Co-Corresponding Author
    🧫 Review Article

Conclusion

Dr. FU Weiwei demonstrates an exceptional and well-rounded profile as a medical researcher with significant contributions to immunology and gastroenterology, supported by prestigious academic training, a robust scientific publication record, impactful patents, and strong conference presence. These achievements, particularly in translational cancer immunology, make Dr. Fu highly suitable for the Best Researcher Award.

Jin-Ju Lei | Molecular Diagnostics | Best Researcher Award

Published on by Molecular Biologist

Dr. Jin-Ju Lei | Molecular Diagnostics | Best Researcher Award 

Doctorate, at Renmin Hospital of Wuhan University, China.

Dr. Jin-Ju Lei is a dedicated and innovative medical doctor currently serving at the Cancer Center of Renmin Hospital, Wuhan University. A pioneer in the development of non-invasive pathological testing for cancer, Dr. Lei has combined her clinical expertise with cutting-edge biomedical research. Her career spans from foundational clinical training to advanced oncology specialization, demonstrating a consistent commitment to improving cancer diagnostics and treatment. Her contributions to oncological research have earned her recognition both in China and internationally, particularly for her work on metastasis mechanisms and cancer biomarkers. With over a decade of experience, she has played an active role in shaping modern cancer diagnostics and remains passionate about translating science into meaningful clinical outcomes. 🌱🔍

Professional Profile

Scopus

🎓 Education

Dr. Lei’s educational foundation was built at Xinxiang Medical University, where she earned her Bachelor’s degree in Clinical Medicine (2005–2010). She pursued advanced medical training and specialization at the prestigious Sun Yat-sen University Cancer Center, obtaining her Doctorate in Oncology (2010–2015). During this period, she received intensive clinical and research training in oncology, with a focus on cancer pathophysiology, molecular diagnostics, and precision medicine. 📚 Her academic path shaped her scientific curiosity, leading to a career that bridges patient care and translational cancer research. The rigorous programs at both institutions enabled her to build a strong command of oncology at both theoretical and applied levels. 🧠📖

🏥 Experience

Dr. Jin-Ju Lei has been serving at the Cancer Center, Renmin Hospital of Wuhan University since 2015. She started as a Resident Doctor (2015–2016) and was quickly promoted to Attending Physician in December 2016, a role she continues to fulfill with excellence. In her clinical duties, she specializes in managing complex cancer cases and developing diagnostic protocols using molecular technologies. Her clinical insight is further supported by her active engagement in research, where she explores novel biomarkers and treatment modalities. 👩‍⚕️ Her long-term experience in a leading hospital has allowed her to contribute to multi-disciplinary teams and collaborative studies, improving cancer detection and patient outcomes. 🔍💼

🧪 Research Interests

Dr. Lei’s research is centered on cancer biomarkers, metastasis mechanisms, and non-invasive diagnostics, particularly in breast, nasopharyngeal, and pancreatic cancers. 🧬 She has played a pivotal role in identifying the suppressive roles of proteins like NOP14 and the prognostic value of unconjugated bilirubin in cancer progression. Her interests also extend to liquid biopsy technologies, where she contributes to innovations like targeting nanoprobes for mRNA detection in circulating malignant cells. Her research aims to enable earlier, safer, and more accurate detection of cancers, ultimately reducing the burden of invasive procedures. Her interdisciplinary approach combines clinical insight with molecular and translational research. 🧫🧠

🏆 Awards

Although not explicitly listed, Dr. Lei’s career demonstrates the hallmarks of a high-achieving medical researcher. Her contributions to SCIE-indexed journals, her co-authorship in influential studies on cancer suppression and diagnostic biomarkers, and her role in developing innovative cancer testing methods position her as a likely nominee for awards in translational medicine, oncology, and medical innovation. 🏅 Her participation in international research collaborations, peer-reviewed publications, and breakthroughs in non-invasive cancer diagnostics signify her impactful role in the field. She is an ideal candidate for award nominations recognizing excellence in medical innovation and cancer research. 🌟

📚Top Noted Publications

Dr. Jin-Ju Lei has co-authored numerous peer-reviewed publications, reflecting her depth of involvement in translational oncology:

  • NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/β-catenin pathway
    Oncotarget, 2015.

    • Impact: Cited by 120+ articles.

    • Summary: Identified NOP14 as a tumor suppressor gene in breast cancer via inhibition of the NRIP1/Wnt/β-catenin signaling pathway.

    • Contribution: Advanced molecular understanding of breast cancer progression and potential therapeutic targets.

  • Unconjugated Bilirubin as a Prognostic Biomarker for Nasopharyngeal Carcinoma
    Cancer Prevention Research, 2016.

    • Impact: Cited by 90+ articles.

    • Summary: Demonstrated that elevated unconjugated bilirubin levels serve as a negative prognostic marker in nasopharyngeal carcinoma patients.

    • Contribution: Proposed a non-invasive and cost-effective biomarker for patient prognosis.

  • Exome sequencing reveals novel mutated genes in pancreatic cancer metastasis
    Cancer Biology & Therapy, 2012.

    • Impact: Cited by 110+ articles.

    • Summary: Used exome sequencing to uncover novel genetic mutations associated with pancreatic cancer metastasis.

    • Contribution: Provided a genomic basis for understanding metastatic behavior in pancreatic cancer.

  • HLA-G expression linked to prognosis in nasopharyngeal carcinoma
    International Journal of Biological Sciences, 2012.

    • Impact: Cited by 60+ articles.

    • Summary: Established a correlation between HLA-G overexpression and poor prognosis in nasopharyngeal carcinoma.

    • Contribution: Contributed to the field of immune evasion mechanisms in cancer.

  • MAGL promotes metastases in nasopharyngeal carcinoma
    International Journal of Clinical and Experimental Pathology, 2014.

    • Impact: Cited by 45+ articles.

    • Summary: Showed that monoacylglycerol lipase (MAGL) enhances metastatic potential in nasopharyngeal carcinoma.

    • Contribution: Linked lipid metabolism enzymes to tumor aggressiveness.

  • Autophagic cell death and radiation sensitization in hepatocellular carcinoma
    World Journal of Gastroenterology, 2017.

    • Impact: Cited by 30+ articles.

    • Summary: Explored autophagic mechanisms that sensitize hepatocellular carcinoma cells to radiation therapy.

    • Contribution: Suggested potential targets to enhance radiotherapy efficacy.

  • First primary cancer patients with second cancer: a population study
    Clinical and Experimental Medicine, 2023.

    • Impact: Rising citations in epidemiological research.

    • Summary: Analyzed population-level data on patients developing second primary cancers.

    • Contribution: Informs cancer surveillance and survivorship care strategies.

  • Innovative treatment for metastatic thyroid-like follicular carcinoma
    Frontiers in Oncology, 2024.

    • Impact: Emerging relevance in rare cancer treatment literature.

    • Summary: Presented a novel therapeutic approach for a rare metastatic renal carcinoma.

    • Contribution: Pioneered strategies in precision oncology for underrepresented cancers.

  • Blood biopsy using nanoprobe for lung cancer mRNA biomarkers
    Applied Physics Reviews, 2025.

    • Impact: High novelty and technological impact.

    • Summary: Developed a nanoprobe-based blood biopsy method for detecting mRNA biomarkers in lung cancer.

    • Contribution: Integrates nanotechnology with non-invasive cancer diagnostics.

Conclusion

Dr. Jin-Ju Lei is an exceptional candidate for the Research for Best Researcher Award. Her unparalleled expertise in clinical oncology, her innovative contributions to non-invasive cancer diagnostics, and her consistent track record of impactful research publications all underscore her suitability for this prestigious recognition. By further expanding her interdisciplinary collaborations and focusing on translational research, Dr. Lei can continue to lead the way in advancing cancer research and treatment.